Pharmaceutical industry – Page 18
-
BusinessBristol-Myers Squibb to buy Celgene for $74 billion
Deal boosts BMS’s cancer and immunology pipeline with 5 drugs in late stage clinical trials
-
ArticleStrength through diversity
Why people should be at the heart of a forward-thinking contract research organisation
-
BusinessGSK and Pfizer joint venture creates new consumer healthcare giant
Enlarged GSK consumer health will have largest market share of any firm and be a leader in key countries
-
-
OpinionHow science shapes our psychology
We learn to embrace the unexpected, follow evidence over opinion and accept that most experiments fail
-
BusinessPharmaceuticals roundup 2018
Merger deals, product approvals and infrastructure changes have been overshadowed by political uncertainty, in Europe and around the world
-
BusinessBayer to cut 12000 jobs
As it integrates Monsanto businesses, Bayer will eliminate around 10% of its global workforce
-
BusinessSartan drug contamination brings cancer uncertainty
Levels of nitrosamines and other carcinogens in affected tablets of valsartan and related drugs similar to smoking 20 cigarettes a day
-
BusinessSensing the sweet spot
Ziylo’s selective glucose-binding molecule could open doors to smart insulin for diabetes
-
OpinionPushing the limits of patent protection
Some methods of extending exclusivity rights raise legal and ethical questions
-
BusinessBreaking the silence of RNA interference drugs
A wave of treatments is set to follow the first approval of an RNAi therapy
-
ReviewBitter Pills: The Global War on Counterfeit Drugs
Muhammad Zaman’s book gives an account of the challenges facing drug regulators worldwide
-
BusinessTransforming PET imaging with silicon
Fuzionaire Diagnostics can add Si–18F radiolabels to a variety of molecules quickly, easily and cheaply
-
OpinionWhat would a 1980s student make of modern research?
Nano- and macromolecular science might make for a shocking read in the launderette
-
BusinessLords criticise post-Brexit regulation plans
Current lack of preparedness risks ‘cliff-edge’ on exit day, committee warns
-
OpinionPassing through checkpoints
A new breed of cancer treatments highlights what’s possible when industry concentrates its efforts
-
BusinessSmall biocides companies face uncertain fate
Cost and complexity of European law hampers innovation and excludes SMEs
-
BusinessCancer immunotherapy spreads rapidly
New approvals and expanded use for checkpoint inhibitor drugs illustrate the power of Nobel-winning science
-
OpinionThe projects drug companies wish they’d never started
Failures are common in drug research, but some are bigger than others
-
ResearchRemote controlled self-optimising flow synthesis
Online interface could allow virtual sharing of complex kit, and enable simple improvement of reaction conditions